Veterinary Medicines

Prinocate 100 mg/25 mg Spot-on Solution for Medium Dogs

Authorised
  • Imidacloprid
  • Moxidectin
Download as PDF

Product identification

Medicine name:
Prinocate 100 mg/25 mg spot-on solution for medium dogs
Prinocate 100 mg/25 mg Spot-on Solution for Medium Dogs
Active substance:
  • Imidacloprid
  • Moxidectin
Target species:
  • Dog
Route of administration:
  • Spot-on use

Product details

Active substance and strength:
  • Imidacloprid
    100.00
    milligram(s)
    /
    1.00
    Pipette
  • Moxidectin
    25.00
    milligram(s)
    /
    1.00
    Pipette
Pharmaceutical form:
  • Spot-on solution
Withdrawal period by route of administration:
  • Spot-on use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP54AB52
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • United Kingdom (Northern Ireland)
Package description:
  • A white polypropylene (PP) unit dose pipette with a closure with a spike composed of high density polyethylene (HDPE) orpolyoxymethylene (POM) or polypropylene (PP) packed into a laminated triplex bag composed of polyester (PETP), aluminium(Al) and low density polyetylene (LDPE).Cardboard box containing 48 pipettes.
  • A white polypropylene (PP) unit dose pipette with a closure with a spike composed of high density polyethylene (HDPE) orpolyoxymethylene (POM) or polypropylene (PP) packed into a laminated triplex bag composed of polyester (PETP), aluminium(Al) and low density polyetylene (LDPE).Cardboard box containing 24 pipettes.
  • A white polypropylene (PP) unit dose pipette with a closure with a spike composed of high density polyethylene (HDPE) orpolyoxymethylene (POM) or polypropylene (PP) packed into a laminated triplex bag composed of polyester (PETP), aluminium(Al) and low density polyetylene (LDPE).Cardboard box containing 6 pipettes.
  • A white polypropylene (PP) unit dose pipette with a closure with a spike composed of high density polyethylene (HDPE) orpolyoxymethylene (POM) or polypropylene (PP) packed into a laminated triplex bag composed of polyester (PETP), aluminium(Al) and low density polyetylene (LDPE).Cardboard box containing 4 pipettes.
  • A white polypropylene (PP) unit dose pipette with a closure with a spike composed of high density polyethylene (HDPE) orpolyoxymethylene (POM) or polypropylene (PP) packed into a laminated triplex bag composed of polyester (PETP), aluminium(Al) and low density polyetylene (LDPE).Cardboard box containing 3 pipettes.
  • A white polypropylene (PP) unit dose pipette with a closure with a spike composed of high density polyethylene (HDPE) orpolyoxymethylene (POM) or polypropylene (PP) packed into a laminated triplex bag composed of polyester (PETP), aluminium(Al) and low density polyetylene (LDPE).Cardboard box containing 1 pipette.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application (Article 13(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • KRKA tovarna zdravil d.d. Novo mesto
Marketing authorisation date:
Manufacturing sites for batch release:
  • Krka d.d. Novo Mesto
Responsible authority:
  • The Veterinary Medicines Directorate
Authorisation number:
  • Vm 01656/4184
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0392/004
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Estonia
  • France
  • Greece
  • Hungary
  • Italy
  • Latvia
  • Lithuania
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 28/01/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."